For example, a polo-like Kinase 1 (PLK1) inhibitor could sensitize esophageal squamous cell carcinoma (ESCC) cells to cisplatin by inhibiting the DNA damage repair pathway and inducing Bax/caspase3/GSDME pathway-mediated pyroptosis. This evidence concerns the gene PLK1 and esophageal squamous cell carcinoma.